Page 1

Exhibit 99.3 ADC THERAPEUTICS ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates ZYNLONTAⓇ ( loncastuximab tesirine - lpyl ) third quarter 2021 net sales of $ 13.1 million Financing agreement with Health Care Royalty for up to $ 325 million Company to host conference call today at 8:30 a.m. EDT Lausanne , Switzerland , November 2 , 2021 - ADC Therapeutics SA ( NYSE : ADCT ) , a commercial - stage biotechnology company improving the lives of those affected by cancer with its next - generation , targeted antibody drug conjugates ( ADCs ) for patients with hematologic malignancies and solid tumors , today reported financial results for the third quarter ended September 30 , 2021 and provided business updates . " We are pleased with the momentum of the ZYNLONTAⓇ launch to date and the positive reception from the physician community . Top priorities for the company remain driving the continued growth of ZYNLONTA and developing the longer - term potential of ZYNLONTA for patients , " said Chris Martin , PhD , Chief Executive Officer of ADC Therapeutics . " We are also excited by the progress of our diverse clinical - stage pipeline in both hematology and solid tumors . " Recent Highlights and Developments ZYNLONTA • ZYNLONTA generated net sales of $ 13.1 million in the third quarter of 2021 , the first full quarter of sales . • • • • • Academic centers represented over 50 % of total volume with an approximately 50/50 split between academic and community accounts in the third quarter . The Company continued to initiate new accounts and increase volume from existing and prioritized accounts , including National Comprehensive Cancer Network ( NCCN ) centers . Brand aided and unaided awareness , perception and intent to prescribe continued to increase through the quarter . Broad payer access has been achieved , with no barriers encountered to date . A comprehensive patient support program , Advancing Patient Support , is available to patients . The Company continued to operate efficiently in the dynamic COVID environment . The sales and medical teams are executing with a hybrid model conducting both virtual and face - to - face interactions according to customer preferences and local conditions .